sb 202190 has been researched along with Diabetes Mellitus, Type 2 in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Purves, T | 1 |
| Middlemas, A | 1 |
| Agthong, S | 1 |
| Jude, EB | 1 |
| Boulton, AJ | 1 |
| Fernyhough, P | 1 |
| Tomlinson, DR | 1 |
1 other study available for sb 202190 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.
Topics: Animals; Butadienes; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Melli | 2001 |